Wang L, Ruan M, Lei B, et al. - In pulmonary lesions of advanced non-small-cell lung cancer (NSCLC), the present study sought to assess if 2-deoxy-2( ¹⁸F)fluoro-D-glucose ( ¹⁸F-FDG) combined positron emission tomography and computed tomography (PET/CT)  could predict programmed cell death ligand-1 (PDL1) expression status. Researchers performed a retrospective study with 133 untreated stage IIIB-IV NSCLC patients who had undergone pulmonary lesion biopsy for PDL1 immunochemistry 1 to 4 weeks following ¹⁸F-FDG PET/CT scanning and were randomized to cohorts for modelling and validation of PDL1 expression predictors. They ascertained mean and maximum standard uptake values, metabolic tumor volume, and total lesion glycolysis (pTLG) of primary lesions. It was shown that pSUVmax on ¹⁸F-FDG PET/CT was found to be a possible biomarker for pPDL1 TPS < 1%, 1-49%, and ≥ 50% in untreated stage IIIB-IV NSCLC, and may be useful for ascertaining immunotherapeutic strategy for advanced NSCLC.